The 7 major lamellar ichthyosis markets reached a value of US$ 5.1 Million in 2023. Looking forward, the publisher expects the 7MM to reach US$ 8.1 Million by 2034, exhibiting a growth rate (CAGR) of 5.27% during 2023-2034.
The lamellar ichthyosis market has been comprehensively analyzed in this report titled "Lamellar Ichthyosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Lamellar ichthyosis is a rare and inherited skin disorder that falls under the broader category of ichthyosis, which refers to a group of genetic conditions characterized by dry, scaly skin. This particular type is caused by mutations in the gene responsible for forming a protein called transglutaminase-1, leading to the abnormal development of the skin's protective barrier. The symptoms of the ailment typically manifest at birth or within the first few weeks of life. Individuals suffering from the illness may present with thick, plate-like scales covering large areas of their body, often resembling fish scales. The skin can be dry, rough, and prone to cracking, which can cause discomfort and susceptibility to infections. Moreover, these scales may affect the patient's range of motion and lead to restricted movement. The diagnosis of lamellar ichthyosis involves a thorough examination of the skin and family history analysis. Skin biopsies and genetic testing are also crucial steps in confirming the condition.
The rising prevalence of somatic mutations in the TGM1 gene, which result in the impaired production of the enzyme transglutaminase-1, leading to the buildup of scale-like skin, particularly affecting the face and body regions, is primarily driving the lamellar ichthyosis market. In addition to this, the escalating adoption of numerous effective medications, including emollients, keratolytics, retinoids, etc., to alleviate symptoms of the ailment and enhance skin barrier function is fostering a positive outlook for the market. Moreover, the widespread implementation of physical and occupational therapies to increase treatment response is further bolstering the market growth. These therapies play a crucial role in managing the condition by promoting mobility, improving limb function, and enhancing overall motor skills. Apart from this, the increasing utilization of phototherapy, since it involves exposing the affected skin to controlled levels of ultraviolet light, thereby boosting the quality of life for individuals suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy that works by introducing functional genetic material to correct or replace the faulty TGM1 gene responsible for the disease, providing long-term relief to patients, is expected to drive the lamellar ichthyosis market during the forecast period.
This report provides an exhaustive analysis of the lamellar ichthyosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for lamellar ichthyosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lamellar ichthyosis market in any manner.
The lamellar ichthyosis market has been comprehensively analyzed in this report titled "Lamellar Ichthyosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Lamellar ichthyosis is a rare and inherited skin disorder that falls under the broader category of ichthyosis, which refers to a group of genetic conditions characterized by dry, scaly skin. This particular type is caused by mutations in the gene responsible for forming a protein called transglutaminase-1, leading to the abnormal development of the skin's protective barrier. The symptoms of the ailment typically manifest at birth or within the first few weeks of life. Individuals suffering from the illness may present with thick, plate-like scales covering large areas of their body, often resembling fish scales. The skin can be dry, rough, and prone to cracking, which can cause discomfort and susceptibility to infections. Moreover, these scales may affect the patient's range of motion and lead to restricted movement. The diagnosis of lamellar ichthyosis involves a thorough examination of the skin and family history analysis. Skin biopsies and genetic testing are also crucial steps in confirming the condition.
The rising prevalence of somatic mutations in the TGM1 gene, which result in the impaired production of the enzyme transglutaminase-1, leading to the buildup of scale-like skin, particularly affecting the face and body regions, is primarily driving the lamellar ichthyosis market. In addition to this, the escalating adoption of numerous effective medications, including emollients, keratolytics, retinoids, etc., to alleviate symptoms of the ailment and enhance skin barrier function is fostering a positive outlook for the market. Moreover, the widespread implementation of physical and occupational therapies to increase treatment response is further bolstering the market growth. These therapies play a crucial role in managing the condition by promoting mobility, improving limb function, and enhancing overall motor skills. Apart from this, the increasing utilization of phototherapy, since it involves exposing the affected skin to controlled levels of ultraviolet light, thereby boosting the quality of life for individuals suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy that works by introducing functional genetic material to correct or replace the faulty TGM1 gene responsible for the disease, providing long-term relief to patients, is expected to drive the lamellar ichthyosis market during the forecast period.
This report provides an exhaustive analysis of the lamellar ichthyosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for lamellar ichthyosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lamellar ichthyosis market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the lamellar ichthyosis market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the lamellar ichthyosis market
Competitive Landscape:
This report also provides a detailed analysis of the current lamellar ichthyosis marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the lamellar ichthyosis market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the lamellar ichthyosis market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the lamellar ichthyosis market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of lamellar ichthyosis across the seven major markets?
- What is the number of prevalent cases (2018-2034) of lamellar ichthyosis by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of lamellar ichthyosis by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with lamellar ichthyosis across the seven major markets?
- What is the size of the lamellar ichthyosis patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of lamellar ichthyosis?
- What will be the growth rate of patients across the seven major markets?
Lamellar Ichthyosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for lamellar ichthyosis drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lamellar ichthyosis market?
- What are the key regulatory events related to the lamellar ichthyosis market?
- What is the structure of clinical trial landscape by status related to the lamellar ichthyosis market?
- What is the structure of clinical trial landscape by phase related to the lamellar ichthyosis market?
- What is the structure of clinical trial landscape by route of administration related to the lamellar ichthyosis market?
Table of Contents
?1 Preface3 Executive Summary6 Patient Journey9 Lamellar Ichthyosis - Unmet Needs10 Lamellar Ichthyosis - Key Endpoints of Treatment13. Lamellar Ichthyosis - Attribute Analysis of Key Marketed and Pipeline Drugs16 Lamellar Ichthyosis - Recent Events and Inputs From Key Opinion Leaders18 Lamellar Ichthyosis Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Lamellar Ichthyosis - Introduction
5 Lamellar Ichthyosis - Disease Overview
7 Lamellar Ichthyosis - Epidemiology and Patient Population
8 Lamellar Ichthyosis - Treatment Algorithm, Guidelines, and Medical Practices
11 Lamellar Ichthyosis - Marketed Products
12 Lamellar Ichthyosis - Pipeline Drugs
14. Lamellar Ichthyosis - Clinical Trial Landscape
15 Lamellar Ichthyosis - Market Scenario
17 Lamellar Ichthyosis Market - SWOT Analysis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 136 |
| Published | May 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 5.1 Million |
| Forecasted Market Value ( USD | $ 8.1 Million |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | Global |
